Welcome to our dedicated page for Avita Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AVITA Medical, Inc. (RCEL) SEC filings page brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q. As a therapeutic acute wound care company focused on the RECELL System and related wound care technologies, AVITA Medical uses these filings to report on its financial condition, capital structure, governance, and material business developments.
In its Form 8-K filings, AVITA Medical has disclosed material definitive agreements such as senior secured credit facilities, amendments to existing credit agreements, and related covenants tied to trailing twelve-month revenue. These documents detail loan terms, revenue requirements, warrant issuances, and security interests in company assets. Other 8-K reports cover equity placements, including CHESS Depositary Interests issued to institutional and professional investors, and governance matters such as board appointments, executive transitions, and director compensation arrangements.
Periodic reports like the Form 10-K and Form 10-Q (accessible from this filings stream when available) provide broader information on AVITA Medical’s business, including discussion of its therapeutic acute wound care platform, risk factors, and consolidated financial statements. Investors can review these filings to understand how the company describes its RECELL System, PermeaDerm, and Cohealyx products, as well as its regulatory environment and key risk considerations.
Stock Titan’s platform enhances access to these documents with AI-powered summaries that explain the significance of complex filings, from credit agreements and warrant terms to revenue covenants and equity raises. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K, and Form 4 insider transaction reports are available as they are filed, while AI-generated highlights help readers quickly identify items related to financing, governance, and operational strategy for AVITA Medical.
AVITA Medical, Inc. appointed experienced healthcare executive Joe Woody to its Board of Directors, effective January 1, 2026, to serve until the 2026 Annual Meeting of Stockholders. He will sit on each of the Board’s committees and has been determined to be an independent director under applicable standards. The company states that he has no appointment-related arrangements, family relationships with directors or executives, or material related-party transactions requiring disclosure.
Woody brings more than two decades of medical technology leadership, including serving as CEO of Avanos Medical and President and CEO of Acelity Holdings, as well as senior roles at Covidien and Smith & Nephew and long-term service on the AdvaMed board. Under an offer letter effective January 1, 2026, he will receive $92,500 in annual cash compensation for Board service and an initial equity grant valued at $210,000, with about 30% in stock options and 70% in restricted stock units, plus eligibility for annual equity grants, all subject to shareholder approval.
AVITA Medical (RCEL) filed its Q3 2025 10‑Q, reporting lower revenue and a going concern warning. Total revenue was $17.1 million for the quarter, down from $19.5 million a year ago. Net loss was $13.2 million versus $16.2 million in the prior year period. For the nine months, revenue reached $54.0 million and net loss was $37.0 million.
Cash, cash equivalents, and marketable securities were $23.3 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern due to expected non‑compliance with a minimum cash covenant under its senior secured credit facility. The loan facility balance of $42.4 million was classified as current. AVITA obtained revenue covenant waivers for Q1–Q3 2025 and amended future thresholds.
To bolster liquidity, AVITA completed an August 12, 2025 private placement raising $14.8 million gross (3,440,377 common share equivalents via 17,201,886 CDIs). Shares outstanding were 30,493,111 as of November 3, 2025. Lease revenue from RECELL GO devices was $165,000 in Q3, with product sales the primary driver of revenue.
AVITA Medical (RCEL) amended its credit agreement with affiliates of OrbiMed Advisors, LLC. The Sixth Amendment sets a trailing 12‑month revenue covenant of $70.0 million for the quarter ending December 31, 2025, while keeping subsequent revenue covenants in place through the Maturity Date.
The lenders also waived a requirement that AVITA’s Form 10‑Q for the quarter ended September 30, 2025 contain no “going concern” or similar qualification. In exchange, AVITA agreed to add $500,000 to the principal balance of the Credit Agreement, with interest on this amount accruing as of November 1, 2025 and payable with the original $40,000,000 principal at maturity or earlier repayment.
Separately, AVITA announced it issued a press release covering third‑quarter results for the period ended September 30, 2025.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 1,138,436 shares of AVITA Medical, Inc. (RCEL) common stock, representing 4.3% of the class. The event triggering the filing is dated 09/30/2025.
BlackRock reports sole voting power over 1,119,786 shares and sole dispositive power over 1,138,436 shares, with 0 shared voting or dispositive power. The filing notes that various persons may have rights to dividends or proceeds, but no single person exceeds five percent of outstanding shares. BlackRock certifies the securities were acquired and are held in the ordinary course of business and not to change or influence control.
AVITA Medical (RCEL) announced leadership changes. Effective October 16, 2025, James Corbett departed as Chief Executive Officer and director; the company stated his departure was not due to any disagreement regarding operations, policies, or practices. The Board appointed Chairman Cary Vance as Interim CEO, and named Jan Reed as Lead Independent Director.
Vance brings nearly 30 years of healthcare leadership experience, including CEO roles at PhotoniCare, Titan Medical, and others. As Interim CEO, he will receive an annual base salary of $702,000 and a guaranteed bonus of $140,000 for fiscal 2025. For fiscal 2026, he is eligible for a target bonus equal to 80% of base salary, with half guaranteed and half tied to performance metrics, subject to continued service through the one-year anniversary of the effective date. He will forgo Board compensation while serving as Interim CEO and will be reimbursed for commuting expenses per company policy.
Avita Medical director Robert McNamara reported a personal purchase of company stock on 08/28/2025. The Form 4 shows a purchase of 10,000 shares of Avita Medical common stock at $4.50 per share. After the transaction he beneficially owns 86,771 shares, a figure the filing notes includes unvested restricted stock units. The filing identifies McNamara as a director and was signed by an authorized power of attorney on 08/29/2025. The document lists no derivative transactions and provides no additional financial results or forward-looking statements.
Insider purchase reported: Avita Medical (RCEL) CFO David O'Toole purchased 2,000 shares of the company's common stock on 08/26/2025 at a price of $4.52 per share. After the transaction he beneficially owns 31,657 shares in a direct capacity. The filing shows no amendments and no derivative transactions were reported.
Avita Medical, Inc. (RCEL) director Robert McNamara reported a purchase of 10,000 shares of the company's common stock on 08/19/2025 at a price of $5.00 per share, bringing his beneficial ownership to 76,771 shares. The Form 4 was signed by power of attorney on 08/20/2025.
AVITA Medical, Inc. entered into a placement agreement to sell 17,201,886 CHESS Depositary Interests (CDIs) to Australian institutional and professional investors at approximately AU$1.32 per CDI. Five CDIs represent one share of common stock.
The Company expects aggregate proceeds of about US$15 million (A$22.7 million) and will pay placement agent fees valued at approximately US$0.8 million in cash and CDIs. The unregistered Placement relies on Regulation S for offerings made outside the United States and is expected to close on or about August 19, 2025.
David O'Toole, identified as the Chief Financial Officer, filed a Form 4 reporting a change in beneficial ownership of Avita Medical, Inc. (RCEL). The filing shows he acquired 2,000 shares of common stock on 08/12/2025 at a price of $4.81 per share, increasing his direct holdings to 29,657 shares. The transaction is reported under transaction code P and the Form 4 was filed by one reporting person.